Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)
ID: 355430Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $750K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355430

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-049.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional)" through the National Institute of Allergy and Infectious Diseases (NIAID). This initiative aims to identify critical factors driving TB transmission in high-burden areas and to develop effective measurement and intervention strategies, including low-cost methods to prevent and detect infectious TB. With a total funding amount of $6 million available for 4-5 awards in FY 2025, eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and foreign entities. Applications are due by December 5, 2024, and interested parties can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-049-Full-Announcement.html
    RFA-AI-24-049.html
    The National Institutes of Health (NIH) is announcing a funding opportunity through the National Institute of Allergy and Infectious Diseases (NIAID) titled "Halting Tuberculosis (TB) Transmission" (R01 Clinical Trial Optional). The goal is to identify key factors driving TB transmission in high-burden areas and develop effective measurement and intervention strategies, including low-cost methods to prevent and detect infectious TB. A total of $6 million is available for 4-5 awards in FY 2025, with applications due by December 5, 2024. Eligible applicants include a wide range of organizations, from higher education institutions to nonprofits and foreign entities. Applications should address specific research objectives, such as understanding the role of asymptomatic TB in transmission, and must comply with stringent application instructions. Investigators are encouraged to leverage advancements in technology for data collection and tracking of TB transmission. The review process will evaluate scientific and technical merit, considering factors like significance, innovation, approach, and the qualifications of the research team. This funding aims to support critical research that can significantly impact global health efforts against tuberculosis, one of the leading infectious disease killers worldwide.
    Similar Opportunities
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    Innovative Approaches for TB Prevention and Case Finding to END TB
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement grant titled "Innovative Approaches for TB Prevention and Case Finding to END TB," aimed at developing and evaluating innovative strategies for tuberculosis (TB) prevention and detection. The grant focuses on two main components: preventing TB infection and disease progression in high-burden settings through preventive treatment and nutrition, and finding TB infections, including sub-clinical cases, using new tools across various high-risk populations. With an estimated total program funding of $10 million and an award ceiling of $2 million, the CDC expects to make two awards under this opportunity. Interested applicants can submit their proposals electronically by March 3, 2025, and should direct any inquiries to Hoang Dang at hdang@cdc.gov.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt)" aimed at supporting the development of long-acting/sustained release (LA/SR) technologies for the prevention and treatment of HIV and associated co-infections such as tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). This initiative seeks to fund preclinical activities that will advance these technologies toward submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA), with a focus on ensuring safety and efficacy through rigorous studies. The program is particularly significant as it addresses public health challenges related to infectious diseases that disproportionately affect individuals living with HIV, and it will provide approximately $4 million to support 3-5 awards, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Tobacco Regulatory Science (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Tobacco Regulatory Science (R01 Clinical Trial Optional)" funding opportunity, aimed at supporting biomedical and behavioral research to inform the regulation of tobacco products and protect public health. This initiative seeks R01 research project grant applications that address key research priorities, including the composition and design of tobacco products, toxicity assessments, addiction studies, and the health effects of tobacco use. A total of up to six R01 grants, with a combined funding of $4 million for fiscal year 2024, will be awarded to eligible applicants, which include a diverse range of institutions and organizations. Interested parties should submit their applications by May 4, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html for further details.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.